{"favorite_id": 10041, "calc_type": "", "dosing": false, "full_title_en": "Cytokine Release Syndrome (CRS) Grading", "short_title_en": "Cytokine Release Syndrome (CRS) Grading", "medium_description_en": "Assesses severity of CRS in patients on immunotherapy.", "short_description_en": "CRS severity. ", "before_use": "", "instructions_en": "<p><span id=\"docs-internal-guid-7ee9c317-ce34-44e3-05d3-b365d29a8aca\">Use in patients receiving immunotherapy for cancer.</span></p>", "purpose_en": ["Diagnosis", "Treatment"], "disease_en": ["Cancer", "Chemotherapy", "Hematologic Malignancy"], "specialty_en": ["Critical Care", "Family Practice", "Hematology and Oncology", "Internal Medicine", "Primary Care", "Radiation Oncology"], "chief_complaint_en": ["Dyspnea", "Fever", "Headache", "Rash", "Shortness of Breath"], "system_en": ["Hematologic", "Immunologic", "Oncologic"], "search_abbreviation_en": ["CRS grade", "cytokine toxicity", "cytokine release syndrome", "CRS scale", "CRS grading"], "slug": "cytokine-release-syndrome-crs-grading", "seo": {"meta_description_en": "The Cytokine Release Syndrome Grading scales the degrees of severity of CRS. ", "keywords_en": "Cytokine release syndrome, CRS grading "}, "content": {"how_to_use": {"use_case_en": "<p><span id=\"docs-internal-guid-7d4a8816-ce34-73b5-f7db-188289cbf486\">Patients receiving immunotherapy for cancer with signs of cytokine-mediated immunological reactions and multi-organ dysfunction.</span></p>", "pearls_pitfalls_en": "<p><span id=\"docs-internal-guid-5fac9813-4323-420a-8cdd-d16e9d2fdede\"></span><span id=\"docs-internal-guid-30338cbf-ce36-4066-ba59-7ee7d4ec9c82\"></span></p>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Do not forget coagulopathy as organ dysfunction.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">High-dose vasopressors need to be on board for &ge;3 hours in order to be assigned grade 3.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Consider corticosteroids at 24 hours if no improvement.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Most patients receiving immunological therapies have complicated ongoing processes and require specialized care. Clinical expertise, vigilance, and frequent follow-up are key to recognizing CRS and not attributing signs and symptoms to an alternate cause (e.g. infection).</p>\n</li>\n</ul>", "why_use_en": "<p><span id=\"docs-internal-guid-b1c45c37-ce36-ac46-67ac-0aa0145bce08\">Helps guide interventions for patients receiving immunological therapies for cancer.</span></p>"}, "next_steps": {"advice_en": "<p><span id=\"docs-internal-guid-25b4b481-ce36-d2fc-922d-bad470ab9f7b\">Clinical judgment should be exercised at all times regarding the observed time course of symptoms and the patient's functional reserve. Tailoring interventions and moving to second-line agents, ruling out other causes, and follow-up are key.</span></p>", "management_en": "<p><span id=\"docs-internal-guid-e7a5c36b-4326-e96f-cef2-77b07bc55cf6\"></span><span id=\"docs-internal-guid-fd803b4d-ce37-2c4a-4696-ed118d12395d\"></span></p>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Monitoring and aggressive supportive care should be considered in order to prevent irreversible end-organ damage.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Consider ICU setting (1:1 nursing care).</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Consider involving expert consultative services.</p>\n</li>\n</ul>", "critical_actions_en": "<p><span id=\"docs-internal-guid-565b102e-ce37-85ad-d52d-c464cba16ff8\">Always investigate for alternate causes such as infection, tumor lysis syndrome, or organ dysfunction. Always evaluate for end-organ damage.</span></p>"}, "about": {"formula_en": "<p dir=\"ltr\">Selection of the appropriate symptoms/signs:</p>\n<div dir=\"ltr\">\n<table><colgroup><col width=\"327\" /><col width=\"63\" /></colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>Toxicity </strong></p>\n</td>\n<td>\n<p dir=\"ltr\"><strong>Grade</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Symptoms not life-threatening; only symptomatic treatment required (fever, nausea, fatigue, headache, myalgias, malaise)</p>\n</td>\n<td>\n<p dir=\"ltr\">1</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Moderate intervention required for response: oxygen requirement &lt;40%, hypotension responsive to fluids, low dose of one pressor, or grade 2 organ toxicity</p>\n</td>\n<td>\n<p dir=\"ltr\">2</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Aggressive intervention required for response: oxygen requirement &ge;40%, hypotension requiring high dose/multiple pressors*, grade 3 organ toxicity, or grade 4 transaminitis</p>\n</td>\n<td>\n<p dir=\"ltr\">3</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Life-threatening symptoms: ventilator required, or grade 4 organ toxicity (excluding transaminitis)</p>\n</td>\n<td>\n<p dir=\"ltr\">4</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Death</p>\n</td>\n<td>\n<p dir=\"ltr\">5</p>\n</td>\n</tr>\n</tbody>\n</table>\n</div>\n<p dir=\"ltr\">Grade organ toxicity by <a href=\"https://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf\" target=\"_blank\">Common Terminology Criteria for Adverse Events (CTCAE) v4.0</a>.</p>\n<p></p>\n<p dir=\"ltr\">*High dose pressors defined as any of the following for &ge;3 hours:</p>\n<div dir=\"ltr\">\n<table><colgroup><col width=\"102\" /><col width=\"119\" /><col width=\"201\" /></colgroup>\n<tbody>\n<tr>\n<td colspan=\"2\">\n<p dir=\"ltr\"><strong>Pressor</strong></p>\n</td>\n<td>\n<p dir=\"ltr\"><strong>Dose**</strong></p>\n</td>\n</tr>\n<tr>\n<td rowspan=\"4\">\n<p dir=\"ltr\">Monotherapy</p>\n</td>\n<td>\n<p dir=\"ltr\">NorEPINEPHrine</p>\n</td>\n<td>\n<p dir=\"ltr\">&ge;20 &mu;g/kg/min</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">DOPamine</p>\n</td>\n<td>\n<p dir=\"ltr\">&ge;10 &mu;g/kg/min</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Phenylephrine</p>\n</td>\n<td>\n<p dir=\"ltr\">&ge;200 &mu;g/kg/min</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">EPINEPHrine</p>\n</td>\n<td>\n<p dir=\"ltr\">&ge;10 &mu;g/kg/min</p>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\">\n<p dir=\"ltr\">If on vasopressin</p>\n</td>\n<td>\n<p dir=\"ltr\">Vasopressin + norEPINEPHrine equivalent of&nbsp;&ge;10 &mu;g/kg/min</p>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\">\n<p dir=\"ltr\">If on combination pressors (excluding vasopressin)</p>\n</td>\n<td>\n<p dir=\"ltr\">NorEPINEPHrine equivalent of&nbsp;&ge;20 &mu;g/kg/min</p>\n</td>\n</tr>\n</tbody>\n</table>\n</div>\n<p dir=\"ltr\">**VASST Trial vasopressor equivalent equation: norEPINEPHrine equivalent dose = [norEPINEPHrine (&mu;g/min)] + [DOPamine (&mu;g/kg/min) / 2] + [EPINEPHrine (&mu;g/min)] + [phenylephrine (&mu;g/min) / 10].</p>\n<p><span style=\"font-size: 10pt; font-family: Arial; color: #0000ff; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">&nbsp;</span></p>", "more_info_en": "<p dir=\"ltr\">Interpretation:</p>\n<div dir=\"ltr\">\n<div dir=\"ltr\">\n<table>\n<tbody>\n<tr style=\"height: 0pt;\">\n<td>\n<p dir=\"ltr\"><strong>CRS Grade</strong></p>\n</td>\n<td>\n<p dir=\"ltr\"><strong>Treatment </strong></p>\n</td>\n</tr>\n<tr style=\"height: 0pt;\">\n<td>\n<p dir=\"ltr\">Grade 1 CRS</p>\n</td>\n<td>\n<p dir=\"ltr\">Vigilant supportive care, assess for infection (treat fever and neutropenia if present; monitor fluid balance; give antipyretics/analgesics as needed)</p>\n</td>\n</tr>\n<tr style=\"height: 20pt;\">\n<td>\n<p dir=\"ltr\">Grade 2 CRS, no extensive comorbidities or older age</p>\n</td>\n<td>\n<p dir=\"ltr\">Vigilant supportive care (monitor cardiac and other organ function closely)</p>\n</td>\n</tr>\n<tr style=\"height: 20pt;\">\n<td rowspan=\"2\">\n<p dir=\"ltr\">Grade 2 CRS with extensive comorbidities or older age</p>\n</td>\n<td rowspan=\"3\">\n<p dir=\"ltr\">Vigilant supportive care, tocilizumab &plusmn; corticosteroids</p>\n</td>\n</tr>\n<tr style=\"height: 20pt;\"></tr>\n<tr style=\"height: 20pt;\">\n<td>\n<p dir=\"ltr\">Grade 3-4 CRS</p>\n</td>\n</tr>\n<tr style=\"height: 20pt;\">\n<td>\n<p dir=\"ltr\">Grade 5</p>\n</td>\n<td>\n<p dir=\"ltr\">Not applicable</p>\n</td>\n</tr>\n</tbody>\n</table>\n</div>\n</div>\n<p><span id=\"docs-internal-guid-5e46b5aa-c874-e893-2eaa-f4139bd0f554\">From <a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4093680/\" target=\"_blank\">Lee 2014</a>.</span></p>", "evidence_based_medicine_en": "<p><span id=\"docs-internal-guid-741c3fe7-ce37-acb7-95f7-a3d248302d4e\">The interventions listed are based on institutional practices where these therapies have been developed. They have been widely adopted and used in the clinical trials for these therapies. They are also included in the FDA labels of some of these medications.</span></p>", "references_list": {"Original/Primary Reference": [{"href": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4093680/ ", "text": "Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188-95. "}], "Other References": [{"href": "https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciy152/4898181?redirectedFrom=fulltext ", "text": "Park JH, Romero FA, Taur Y, et al. Cytokine Release Syndrome Grade is a Predictive Marker for Infections in Relapsed or Refractory B-cell All Patients Treated with CAR T Cells. Clin Infect Dis. 2018."}, {"href": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833070/ ", "text": "Porter D, Frey N, Wood PA, Weng Y, Grupp SA. Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel. J Hematol Oncol. 2018;11(1):35."}], "Validation": [], "Clinical Practice Guidelines": [], "Manufacturer Website": [], "Outcomes": []}}, "contributor": {"expert_name": [{"description": "", "firstName": "Joseph", "img": "", "lastName": "Maakaron", "name": "Joseph Maakaron, MD ", "target": "", "signedCOI": false, "hasDisclosure": []}]}, "creator": [], "reviewer": {"expert_name": []}, "related_resources": {"mdcalc_rating": [], "guidelines": [], "teaching": [], "videos": [], "interests": [], "partner_contact": [], "sdm_tool": []}}, "input_schema": [{"type": "radio", "label_en": "Toxicity", "default": 0, "conditionality": "", "show_points": false, "tips_en": "See <a href=\"#evidence\">Evidence</a> for grading organ toxicity and definitions of high-dose pressors", "optional": false, "options": [{"label": "Symptoms not life-threatening; only symptomatic treatment required (fever, nausea, fatigue, headache, myalgias, malaise)", "value": 1}, {"label": "Moderate intervention required for response: oxygen requirement <40%, hypotension responsive to fluids, low dose of one pressor, or grade 2 organ toxicity", "value": 2}, {"label": "Aggressive intervention required for response: oxygen requirement \u226540%, hypotension requiring high dose/multiple pressors, grade 3 organ toxicity, or grade 4 transaminitis", "value": 3}, {"label": "Life-threatening symptoms: ventilator required, or grade 4 organ toxicity (excluding transaminitis)", "value": 4}, {"label": "Death", "value": 5}], "name": "toxicity"}, {"type": "toggle", "label_en": "Extensive comorbidities or older age", "default": 0, "conditionality": "toxicity ==2", "show_points": false, "tips_en": "", "optional": false, "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "name": "comorbidities"}], "md5": "", "related_calcs": [{"calcId": 3925, "short_title_en": "Fong Score", "slug": "fong-clinical-risk-score-colorectal-cancer-recurrence"}, {"calcId": 10040, "short_title_en": "Duval/CIBMTR Score", "slug": "duval-cibmtr-score-acute-myelogenous-leukemia-aml-survival"}, {"calcId": 19, "short_title_en": "Absolute Neutrophil Count", "slug": "absolute-neutrophil-count-anc"}]}